Quote this publication Share Print


Opinions on drugs - Posted on Dec 22 2009

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for hospital use.


Clinical Benefit


The actual benefit is substantial.

Clinical Added Value


AFINITOR offers a minor IAB (grade IV) in treatment strategy in the treatment of advanced renal cancer following failure of VEGF-targeted therapy.

Contact Us

Évaluation des médicaments

See also